Study on Serum Anti-Mllerian Hormone AMH Levels in Diagnosing and Managing PCOS, POI, and Fertility in Women Undergoing ART

What this Trial Is About

Researchers are evaluating the relationship between Anti-Mllerian hormone AMH levels and conditions such as polycystic ovarian syndrome PCOS, premature ovarian insufficiency POI, and fertility. This prospective observational study aims to understand how AMH can help diagnose PCOS, manage POI, and predict reproductive outcomes in women undergoing assisted reproductive technology ART treatment. The study also looks at how AMH levels correlate with other markers like follicle-stimulating hormone FSH and antral follicle count AFC. The research is sponsored by the Chinese University of Hong Kong and runs from 2022 to 2026. Participants include women attending clinics for PCOS and POI management and those receiving ART treatment. Routine blood tests will measure serum AMH, FSH, luteinizing hormone LH, estradiol, and AFC through transvaginal ultrasound before treatment begins. Remaining serum samples from these tests will be stored and analyzed for the study. The study will also evaluate the types and doses of gonadotropins used for ovarian stimulation during ART. During the study, participants will undergo blood tests and ultrasounds to assess ovarian reserve and hormone levels. Data collected includes AMH levels within 1 to 2 months after recruitment, hormone levels on the first day of ovarian stimulation, total gonadotropin dose, number of oocytes retrieved, clinical pregnancy rates, and live birth rates. Researchers will analyze these results to explore AMHs predictive value for reproductive outcomes. The total participation spans from initial recruitment through pregnancy outcomes for those undergoing ART.

Clinical Application of Serum Anti-Müllerian Hormone (AMH) Measurements